✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Shenzhen Salubris Pharmaceuticals Co Ltd

Common Name
Shenzhen Salubris Pharmaceuticals
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4,087
Ticker
002294
Exchange
Shenzhen Stock Exchange
Description
Shenzhen Salubris Pharmaceuticals Co. Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, production, and sale of a wide range of medicinal produ...

Shenzhen Salubris Pharmaceuticals's GHG Emissions Data Preview

In 2024, Shenzhen Salubris Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Shenzhen Salubris Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)20242023
Total Scope 1
11,399.3a
9,287.9a
Total Scope 2
Unspecified Calculation Method
51,246.3a
41,840.3a
Total Scope 3
N/AN/A
Total Scope 1 Revenue Intensity (tCO2e/$M)
20.7349a
19.6144a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=002294&reporting_period=2024"

Verified Sources Behind Shenzhen Salubris Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Shenzhen Salubris Pharmaceuticals's Prospectus 2025
a. Shenzhen Salubris Pharmaceuticals's Prospectus 2025

Insights into Shenzhen Salubris Pharmaceuticals's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Shenzhen Salubris Pharmaceuticals amounted to 62,645.6 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Shenzhen Salubris Pharmaceuticals increased by 22.53%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Shenzhen Salubris Pharmaceuticals's Scope 1 Emissions Over Time

2023202403 k6 k9 k12 ktCO2e+23%
  • Total Scope 1
  • Year-over-Year Change

What are Shenzhen Salubris Pharmaceuticals's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Shenzhen Salubris Pharmaceuticals were 11,399.3 metric tons of CO₂ equivalent (tCO₂e).a

Compared to the previous year (2023), Shenzhen Salubris Pharmaceuticals's Scope 1 emissions increased by 22.73%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Shenzhen Salubris Pharmaceuticals's Scope 2 emissions?

In 2024, Shenzhen Salubris Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 51,246.3 tCO₂e without specifying the calculation method.a

Has Shenzhen Salubris Pharmaceuticals reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Shenzhen Salubris Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) rose by 22.48% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya

What methodology does Shenzhen Salubris Pharmaceuticals use for Scope 2 reporting?

In 2024, Shenzhen Salubris Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a

Shenzhen Salubris Pharmaceuticals's Scope 2 Emissions Over Time

20232024015 k30 k45 k60 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Shenzhen Salubris Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Shenzhen Salubris Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 11,399.3 tCO₂e and total revenues of USD 550 millions. This translates into an emissions intensity of 20.73 tCO₂e per millions USD.a

Shenzhen Salubris Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers

2002,00010,000100,000500,000Scope 1 Emissions (tCO2e)502005002,00010,000Revenues (Millions of USD)CR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MApeloa PharmaceuticalYear: 2025Scope 1: 75,760 tCO2eRevenue: $M 1,397Scope 1 Intensity: 54.21 tCO2e/$MZhejiang Huahai PharmaceuticalYear: 2024Scope 1: 58,691 tCO2eRevenue: $M 1,308Scope 1 Intensity: 44.86 tCO2e/$MLivzon Pharmaceutical GroupYear: 2025Scope 1: 175,562 tCO2eRevenue: $M 1,717Scope 1 Intensity: 102.25 tCO2e/$MDizal PharmaceuticalYear: 2025Scope 1: 887 tCO2eRevenue: $M 114Scope 1 Intensity: 7.75 tCO2e/$MChangchun High-TechYear: 2025Scope 1: 133,335 tCO2eRevenue: $M 1,726Scope 1 Intensity: 77.25 tCO2e/$MSimcere Pharmaceutical GroupYear: 2025Scope 1: 5,428 tCO2eRevenue: $M 1,104Scope 1 Intensity: 4.92 tCO2e/$MHumanwell Healthcare (Group)Year: 2025Scope 1: 24,083 tCO2eRevenue: $M 3,423Scope 1 Intensity: 7.04 tCO2e/$MBeijing Tong Ren TangYear: 2025Scope 1: 28,656 tCO2eRevenue: $M 2,465Scope 1 Intensity: 11.63 tCO2e/$MChina Resources SanjiuYear: 2025Scope 1: 61,350 tCO2eRevenue: $M 4,514Scope 1 Intensity: 13.59 tCO2e/$MPorton Pharma SolutionsYear: 2025Scope 1: 9,489 tCO2eRevenue: $M 488Scope 1 Intensity: 19.43 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 864Scope 1 Intensity: 12.44 tCO2e/$MSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 262Scope 1 Intensity: 174.19 tCO2e/$MConsun Pharmaceutical GroupYear: 2025Scope 1: 7,133 tCO2eRevenue: $M 488Scope 1 Intensity: 14.61 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2025Scope 1: 57,658 tCO2eRevenue: $M 787Scope 1 Intensity: 73.28 tCO2e/$MHepalinkYear: 2025Scope 1: 13,483 tCO2eRevenue: $M 777Scope 1 Intensity: 17.36 tCO2e/$MBioKangtaiYear: 2025Scope 1: 15,001 tCO2eRevenue: $M 382Scope 1 Intensity: 39.29 tCO2e/$MSichuan Biokin PharmaceuticalYear: 2025Scope 1: 8,090 tCO2eRevenue: $M 360Scope 1 Intensity: 22.48 tCO2e/$MChengdu Kanghong Pharmaceutical GroupYear: 2025Scope 1: 11,555 tCO2eRevenue: $M 655Scope 1 Intensity: 17.64 tCO2e/$MBetta PharmaceuticalsYear: 2025Scope 1: 1,268 tCO2eRevenue: $M 516Scope 1 Intensity: 2.46 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MDa Ren TangYear: 2025Scope 1: 3,870 tCO2eRevenue: $M 702Scope 1 Intensity: 5.51 tCO2e/$MDong-E-E-JiaoYear: 2024Scope 1: 20,046 tCO2eRevenue: $M 811Scope 1 Intensity: 24.71 tCO2e/$MShenzhen Salubris PharmaceuticalsYear: 2024Scope 1: 11,399 tCO2eRevenue: $M 550Scope 1 Intensity: 20.73 tCO2e/$M

How does Shenzhen Salubris Pharmaceuticals's GHG emissions intensity compare to its peers?

In 2024, Shenzhen Salubris Pharmaceuticals reported a Scope 1 emissions intensity of 20.73 tCO₂e per millions USD. Compared to the peer group median of 19.6, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Shenzhen Salubris Pharmaceuticals rank on GHG emissions intensity within its industry?

In 2024, Shenzhen Salubris Pharmaceuticals ranked 14 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Shenzhen Salubris Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Want Full Access to Shenzhen Salubris Pharmaceuticals's GHG Emissions Dataset?
Start 30-Day Free Trial